BACKGROUND: Despite improvements in diagnostic and therapeutic interventions to combat cardiovascular disease (CVD) in recent decades, there are significant ongoing access gaps and sex disparities in prevention that have not been adequately quantified in China.
C ardiovascular disease (CVD), including coronary heart disease and stroke, accounts for 26.6% and 27.4% of deaths among women and men, globally. 1 In China, however, CVD claims an even higher proportion of loss of life in women (38.9%) and men (35.5%). 1 Prevention is key for patients with established CVD and those at high risk of future CVD events. Risk factor control through evidence-based drug therapy and healthy behaviors are well-recognized cost-effective strategies for reducing CVD risk by up to 80%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Despite improvements in diagnostic and therapeutic interventions to combat CVD in recent decades, significant variations in its prevention according to sex and other sociodemographic characteristics persist across the globe. In particular, it is recognized that women are less likely to be screened for CVD in primary care, 12 have fewer interventions (percutaneous coronary intervention or coronary artery bypass grafting) at the time of myocardial infarction, [13] [14] [15] and are less likely to be prescribed intensive statin therapy after a CVD event, in comparison with men. 16, 17 These factors contribute to an excess mortality from CVD in women in comparison with men, 18 particularly in rural and remote regions. 19, 20 In China, guideline-recommended CVD preventive medication use and risk factor control are suboptimal, 21, 22 but few data exist on sex differences in CVD prevention and long-term management in this massive population. Herein, we describe sex differences in the primary and secondary prevention of CVD in community-dwelling people, and assess any interaction with age, education, residence, and level of affluence or disadvantage.
METHODS

Study Design
A 2-stage, stratified cluster design was used to obtain a representative sample of adults (aged ≥45 years) in the general population, covering 7 geographic regions of China (Northeast, North, Northwest, East, Central, South, and Southwest China). A computer program randomly selected Beijing, the Xinjiang Uyghur Autonomous Region, and the provinces of Henan, Jilin, Guangdong, Yunnan, Jiangxi, and Zhejiang for further sampling. From each city or province, the aim was to survey 4000 residents (living in the area for >6 months) in both urban and rural areas, with 1 to 3 representative communities included in a capital city and 1 to 13 representative villages in a rural area. Accompanied by the administrative staff of a local community or village, trained research staff undertook door-to-door surveys of the community, visiting each home up to 3 times at different times to identify potentially eligible participants. The study was conducted from June 1, 2014, to December 31, 2016 ; the distribution of study sites is shown in Figure I in the online-only Data Supplement. The ethics committee of Beijing Anzhen Hospital approved the study, and written informed consent was obtained from each participant. The data, methods used in analyses, and materials used in the conduct of the research will be made available to researchers for the purposes of reproducing the results upon formal request to the corresponding author.
Data Collection
We invited all eligible individuals to participate in the survey and to undergo a physical examination with laboratory testing at local community centers. Trained research staff administered a standard questionnaire to obtain data on sociodemographics (age, sex, marital status, level of education, household income, health insurance), health behaviors (tobacco use, diet measured by qualitative food frequency questionnaire, physical activity measured by the Global Physical Activity Questionnaire, 23 and alcohol consumption), and self-reported medical history, including that related to CVD (coronary heart disease, stroke/transient ischemic attack, heart failure, and atrial fibrillation); these data were recorded on a purpose-built electronic data capture system that included range and logic checks, and controls for missing data. Quality assurance staff also reviewed the accumulating data. CVD risk factors (hypertension, dyslipidemia, and diabetes mellitus) were assessed by self-reported physician diagnosis, risk factor-related medication use, or abnormal levels directly measured in the study. Participants also had all their regular medicines checked and recorded.
Definitions
CVD was defined as a history of coronary heart disease (self-report of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting), or stroke
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What Is New?
• Chinese women with high cardiovascular disease (CVD) risk, in comparison with men, are less likely to achieve desirable levels of blood pressure, lipid, and body weight control for primary prevention, and women with established CVD are less likely to be using specific guideline-directed medications for secondary prevention. • Overall, younger women (<65 years) receive the least preventive care, whereas rural women have worse risk factor control than those residing in other locations. • Level of education was not associated with sex differences in primary or secondary CVD prevention for men or women.
What Are the Clinical Implications?
• Clear sex inequities for both primary and secondary CVD prevention are highlighted in China, with further studies required to understand the contributing and mitigating factors. • Multifaceted interventions are likely to be needed to improve awareness, empowerment, and the ability of individuals to optimize CVD prevention. 
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(self-report of stroke/ transient ischemic attack, or presence of any consistent focal neurological deficit).
Ten-year CVD (nonfatal myocardial infarction, fatal or nonfatal stroke, and CVD death) risk was estimated according to the PAR CVD risk model (Prediction for ASCVD Risk in China), 24 as recommended in the Chinese CVD prevention guidelines. 25 High risk was defined as a predicted 10-year CVD risk ≥10%. Factors used in the risk prediction model were: age, mean values of ≥2 systolic BP measures; fasting total cholesterol, high-density lipoprotein cholesterol, current smoking (yes/no), and diabetes mellitus (yes/no), body mass index (BMI), waist circumference, geographic region (northern/southern China), resident at urban/rural area, and family history of CVD. Smoking status was defined as self-reported nonsmoker, former smoker (≥1 year), or current smoker. Diabetes mellitus was defined as a fasting blood glucose ≥7.0 mmol/L, taking antidiabetic medicines, or having a previous postprandial blood glucose ≥11.1 mmol/L, hemoglobin A1c ≥7%, or diagnosis of diabetes mellitus. Cholesterol and blood glucose were measured at a central laboratory certified by the College of American Pathologists (GuangZhou Kingmed Testing Science & Technology Co, Ltd). Bodyweight, height, and waist circumference were measured by trained study personnel using standard methods. Beijing, the Xinjiang Uyghur Autonomous Region, and the Henan and Jilin provinces were defined as northern China, whereas the provinces of Guangdong, Yunnan, Jiangxi, and Zhejiang were defined as southern China. Family history of CVD was defined as any parent or lineal brother or sister of a participant had a history of coronary heart disease or stroke.
Hypertension was defined as measured systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, taking antihypertensive medication, or self-report of a previous diagnosis of hypertension. Dyslipidemia was defined as total cholesterol ≥240 mg/dL, low-density lipoprotein cholesterol (LDL-C) ≥160 mg/ dL, taking a statin or other lipid-lowering agent, or a previous diagnosis of dyslipidemia.
Participants were asked about the use of antiplatelet agents (aspirin or clopidogrel), lipid-lowering drugs (statins or other lipid-lowering agents), and BP-lowering drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, β-blockers, and calcium channel antagonists). Open-ended questions were used to capture additional medications, not specifically listed.
We evaluated whether participants had their risk factors controlled according to variable reference categories: BP <130/80 mm Hg; LDL-C <2.6 mmol/L; not a current smoker; BMI between 18.5 and 24.0 kg/m 2 ; and achieving physical activity targets, defined as ≥30 minutes of moderate-intensity leisure-time physical activity on ≥5 days per week or ≥20 minutes of vigorous-intensity leisure-time physical activity on ≥3 days every week, according to the guidelines. 23
Statistical Methods
The overall use of primary and secondary CVD preventive medications and level of risk factor control were estimated in those with either established CVD or at high 10-year risk (≥10%) of CVD, in women and men. Prevalence estimates were generated by the SAS PROC SURVEYFREQ procedure, incorporating 3 steps of adjustment (sampling weighting, nonresponse weighting, and population weighting). Data from the China Population Census in 2010 were used as the standard reference population to calculate weighted prevalence. Categorical variables are shown as n (%), and continuous variables are shown as mean (SD). To account for missing data, we assigned corresponding means and reference groups to the missing continuous and categorical covariates, respectively. Continuous variables were compared by using the unpaired t test, categorical variables by using the χ 2 test. Associations between sex and drug use, and CVD risk factor control, were evaluated using the SAS PROC SURVEYLOGISTIC procedure, with adjustment for sociodemographic and clinically relevant covariates, including age, sex, area of residence (urban versus rural), region, education level, household income, insurance status, occupation, and history of diabetes mellitus, dyslipidemia, hypertension, and heart failure, based on previous reports. 21 Heterogeneity of associations was tested between different subgroups (age, <65 versus ≥65 years; resident, urban versus rural; education level, lower than college versus college or higher) by adding an interaction term into the regression model. Data are reported as adjusted odds ratios (ORs) with 95% CIs for women, versus men as the reference. A 2-sided P value <0.05 was considered statistically significant. All analyses were conducted using SAS software (version 9.4).
RESULTS
A total of 64 893 people were invited to participate from 39 communities (14 urban and 25 rural), and 47 841 (73.7%) completed the survey; response rates were 66.4% and 79.3% in men and women, and of 80.3% and 69.0% in rural and urban residents, respectively ( Table I in (Table) .
Sex Difference in CVD Primary Prevention for High-Risk Individuals
In general, the proportion of primary prevention drug use was low in both sexes, with the use of BP-lowering, 
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modifiable risk factors controlled, with 54%, 40%, and 45% lower odds of meeting BP, LDL-C, and BMI targets, respectively. Conversely, women had a 380% higher odds of being a nonsmoker, and a 29% higher odds of meeting physical activity targets (Figure 1 ).
Sex Difference in CVD Secondary Prevention for Individuals With Established CVD
Secondary preventive medicine use in women was consistently less frequent than that in men; only 39.5%, 16 .4%, and 20.9% of women, in comparison with 46.7%, 22.5%, and 34.2% of men, were using BPlowering, lipid-lowering, and antiplatelet drugs, respectively. Moreover, 48.6% of women, in comparison with 59.8% of men, were taking at least one guidelinerecommended medication. The odds of women taking BP-lowering, lipid-lowering, and antiplatelet drugs, and any indicated drugs, in comparison with men, were 0.79 (95% CI, 0.65-0.95), 0.69 (95% CI, 0.56-0.84), 0.53 (95% CI, 0.45-0.62), and 0.62 (95% CI, 0.52-0.73), respectively ( Figure 1 ). With respect to CVD risk factor control, women with established CVD were more likely to have adequate BP control (35.2% of women versus 28.7% of men, OR, 1.31 [95% CI, 1.14-1.50]) but less likely to meet the recommended LDL-C target ( Sex differences in medication use and risk factor control were significantly different in primary and secondary CVD prevention (all P for interaction ≤0.001 except in achieving LDL-C target (Figure 1 ).
Sex Differences in CVD Prevention, by Age, by Rurality, and by Education
In comparison with older women (aged ≥65 years), sex disparities in those at high CVD risk at a younger age (<65 years) were significantly higher in the use of antiplatelets (OR, 0.58 [95% CI, 0.39-0.88], and 1.20 [95% CI, 0.92-1.56]; P for interaction =0.0005), whereas sex disparities favored younger women in having well-controlled BP (OR, 0.87 [95% CI, 0.55-1.36] and OR, 0.49 [95% CI, 0.40-0.59]; P for interaction =0.0002) and achieving the physical activity goal (OR, 4.18 [95% CI, 2.98-5.86] and OR, 1.43 [95% CI, 1.22-1.67]; P for interaction <0.0001; Figure 2 ). Disparities in younger women who received even fewer CVD medications were more obvious and consistent for secondary prevention, whereas sex disparities favored younger women in having well-controlled BP (OR, Adjusted odds ratios (OR, 95% CI) of women vs men to evaluate the association between sex and individual medication use (antiplatelet, lipid-lowering drug, BP-lowering drug), any drug use, and the achievement of individual risk factor control targets. Men served as the reference group. Age, region (rural, urban), province, education level, occupation, health insurance, annual household income, and comorbidities (heart failure, dyslipidemia, hypertension, diabetes mellitus) were included in the adjustment. Dyslipidemia and hypertension are not included, respectively, in adjustment for risk factor control targets of LDL-C and blood pressure. *Any antiplatelets, any lipid-lowering drugs, or any BP-lowering drugs. BP indicates blood pressure; CVD, cardiovascular disease; and LDL-C, low-density lipoprotein cholesterol. (Figure 3 ). Rural residents demonstrated particularly poor primary CVD prevention, especially with respect to the use of preventive medications. In comparison with their urban counterparts, sex disparities were larger in the use of BP-lowering drugs (OR, 0.71 [95% CI, 0.56-0.90] in rural residents and OR. 1.06 [95% CI, 0.83-1.36] in urban residents; P for interaction =0.01), lipidlowering drugs (OR, 0.45 [95% CI, 0.25-0.79] in rural residents and OR, 1.23 [95% CI, 0.93-1.63] in urban residents; P for interaction =0.04), achieving LDL-C targets 
. Adjusted sex differences in CVD primary prevention, by age, rurality, and education level for participants with high 10-year CVD risk.
Subgroup analysis to evaluate the interaction between sex disparities and age, rurality, and education level, respectively, in CVD primary prevention; expressed as adjusted OR (95% CI) of women vs men in individual medication use (BP-lowering drug, lipid-lowering drug, antiplatelet drug, and any drug use), and individual risk factor control target achievement. Men served as the reference group. Age, region (rural, urban), province, education level, occupation, health insurance, annual household income, comorbidities (heart failure, dyslipidemia, hypertension, diabetes mellitus) were included in the adjustment. Age, region (rural, urban), and education level were not included, respectively, in the evaluation of the interaction between these factors and sex disparities. Dyslipidemia and hypertension are not included, respectively, in adjustment for the risk factor control targets of LDL-C and blood pressure. *Any antiplatelets, any lipid-lowering drugs, or any BPlowering drugs. BP indicates blood pressure; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; and OR, odds ratio. .50] in rural residents, and OR, 0.56 [95% CI, 0.46-0.68] in urban residents; P for interaction =0.03; Figure 2 ). For CVD secondary prevention, sex disparities were not significantly different between rural and urban residents with respect to either preventive drug therapies or in achieving optimal risk factor control ( Figure 3 ). Higher education status was associated with better primary and secondary CVD prevention profiles in both Subgroup analysis to evaluate the interaction between sex disparities and age, rurality, and education level, respectively, in CVD secondary prevention; expressed as adjusted OR (95%CI) of women vs men in individual medication use (BP-lowering drug, lipid-lowering drug, antiplatelet, and any drug use), and individual risk factor control target achievement. Men served as the reference group. Age, region (rural, urban), province, education level, occupation, health insurance, annual household income, and comorbidities (heart failure, dyslipidemia, hypertension, diabetes mellitus) were included in the adjustment. Age, region (rural, urban), and education level were not included, respectively, in the evaluation of the interaction between these factors and sex disparities. Dyslipidemia and hypertension are not included, respectively, in adjustment for the risk factor control targets of LDL-C and blood pressure. *Any antiplatelets, any lipid-lowering drugs, or any BPlowering drugs. BP indicates blood pressure; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; and OR, odds ratio. ORIGINAL RESEARCH ARTICLE women and men, but sex disparities were not different according to education level for both primary and secondary CVD prevention (Figures 2 and 3) .
DISCUSSION
This is the first study to quantify the uptake of primary and secondary CVD prevention strategies in urban and rural China through a sex lens. In providing contemporary sex comparisons in a sample of 9552 individuals with high 10-year CVD risk and 5454 individuals with established CVD in Chinese community-based settings, the study shows the existence of grossly suboptimal overall primary and secondary CVD prevention. In comparison with men, women with established CVD are less likely to be using guideline-directed secondary prevention medications, and those at high CVD risk are less likely to achieve BP, LDL-C, and body weight control. These findings are largely consistent across different age groups, residential areas, and level of education.
Of particular note is that younger women received the least preventive care, and rural women had the worst level of risk factor control in comparison with those in other locations. However, education level was not associated with sex differences in primary or secondary CVD prevention.
Our findings indicate a pressing need for better development of CVD prevention in China. The current primary healthcare system appears to be ineffective at controlling CVD risk factors in those at highest risk, whereas hospitals focusing on treating acute diseases are ignoring long-term disease management and prevention in those with established CVD. 26 Differences in health insurance coverage could help explain some of the disparities in CVD prevention. Although the majority of the rural population (95%) have joined the New Rural Cooperative Medical Scheme, this only provides cover for in-hospital costs, and the requirement for long-term BP-lowering medications, statins, and antiplatelet agents require out-of-pocket payment. 27 Conversely, urban residents usually hold Urban Employee/ Resident Insurance that provides some coverage (70%) of outpatient medication and over-the-counter costs for CVD prevention. This lack of insurance coverage is an important missed opportunity in CVD prevention given the increasing evidence showing that >75% of the CVD burden could potentially be reduced by controlling metabolic and behavioral risk factors. 10, 28 Disadvantaged populations experience the greatest CVD burden and socioeconomic inequalities between women and men, amplifying disparities in CVD risk factor control. It has been reported that sex inequalities in individual incomes appear to make a large contribution to the poor health of women. 29 Although disparities have been observed in the acute care of patients with CVD, 22, 26, 30 data are scarce regarding sex differences in CVD prevention in the massive Chinese population. Because of different health care-seeking behaviors, physicians' sex bias, and different prevalence of CVD risk factors, 31 the profiles of drug therapies and risk factors control in women and men are very different. For women, more attention needs to be paid on lipid control, whereas, for men, smoking and a sedentary lifestyle are the 2 most prevalent CVD risk factors to be addressed, both in primary prevention and secondary prevention.
Understanding the reasons for the observed sex differences is crucial to inform current policy development in China. Our study showed that women, in comparison with men, are 20% to 50% less likely to receive guideline-directed therapies after a diagnosis of CVD. We identified that young women were at particular risk of suboptimal secondary prevention. This may reflect bias within the healthcare system, with low awareness at the physician level that CVD can affect young women. The disparities between women and men were not reduced in urban residents and in those with a high education in our study, suggesting that sex disparities could not be attributed to economic development or general education alone.
CVD secondary prevention medication underuse and poor risk factor control is an issue at a global level, especially in low-middle income countries and rural areas, as indicated in a multinational community study undertaken between 2003 and 2009. 21 Our findings extend previous data from Western countries highlighting that women are less likely to receive guideline-recommended therapy. 13, 16, 18, 32 Gaps and disparities found in our study could give insightful guidance for future interventions, including but not limited to conducting more studies to determine reasons for sex inequities in both primary and secondary prevention, implementing multifaceted interventions to improve patient awareness, empowerment, and self-care ability, embracing polypill strategies, enhancing general practitioner skills and primary care networks for community dwellers.
This study has several important strengths, including its novelty, because there are few data, to the best of our knowledge, concerning sex differences in CVD prevention and management in China. This recent wellconducted national epidemiological study provides useful new data for individuals from both urban and rural communities in China, allowing us to insightfully analyze sex differences in CVD primary and secondary prevention. CVD studies conducted in hospital, clinic, or other settings where patients are followed up by general practitioners, usually lead to an overestimation of secondary preventative medication use and risk factor control. We believe this bias has been minimized in our community-based design. Even so, our study has several limitations. First, although the provinces were randomly selected, the communities and villages were not, raising potential for selection bias. Second, although a February 18, 2020 Circulation. 2020;141:530-539. DOI: 10.1161/CIRCULATIONAHA.119.043731
538
ORIGINAL RESEARCH ARTICLE response rate of 75% is generally considered reasonable, the characteristics of nonresponders might be different from responders. For example, as a consequence of people with limited access to health care being more likely to respond to our invitation, those who did not respond might have had a better profile of risk factor control and use of preventative drugs. Moreover, the lower response in men (66.4%) in comparison with women (79.3%) might have led to an underestimation or overestimation of the sex disparities in adopting preventive health care. Last, despite our efforts to restrict the diagnosis of CVD to having a history of myocardial infarction or stroke, or ever receiving percutaneous coronary intervention or coronary artery bypass grafting therapy, we acknowledge potential misclassification bias from the use of a self-reported questionnaire despite high public awareness of these conditions in China. 33
Conclusions
Despite nationwide efforts to combat CVD, both primary and secondary CVD prevention remain suboptimal in China across both sexes. Our study has shown large differences in primary and secondary CVD prevention profiles between women and men, most notably for women with established CVD being less likely to be taking guideline-directed medications, and those at high CVD risk being less likely than men to have their BP, LDL-C, or BMI well controlled. Effective strategies for CVD prevention in both men and women, with special emphasis on women, are urgently required to improve the health of this large population.
